90
|
Agendia BV
mammaprint dna microarray-based test for prognosis of her2þ early breast cancers Mammaprint Dna Microarray Based Test For Prognosis Of Her2þ Early Breast Cancers, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/mammaprint dna microarray-based test for prognosis of her2þ early breast cancers/product/Agendia BV Average 90 stars, based on 1 article reviews
mammaprint dna microarray-based test for prognosis of her2þ early breast cancers - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |